Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health Q1 Earnings Call Highlights
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Average Price Target from Analysts
Scalable Biotech Manufacturing Unlocks a $14B Market
Fractyl Health Q4 Earnings Call Highlights
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6%
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
Here Are Friday’s Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $7.40 Consensus Price Target from Brokerages
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $7.40 Average PT from Analysts
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang
Fractyl Health, Inc. - Special Call
Fractyl Health says experimental procedure helps maintain weight-loss in study
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
Fractyl Health Announces Proposed Public Offering
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
Fractyl Health: Speculative Buy With Binary Risk
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models